Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin.

CONCLUSION: First-line gemcitabine and cisplatin is an effective and safe treatment for patients with unresectable BTC who do not meet the eligibility criteria for the ABC-02 trial. Median OS, PFS and treatment side effects were comparable between the patients who received chemotherapy (group I vs. group II).
PMID: 29265948 [PubMed - as supplied by publisher]

Source: Acta Oncologica - December 21, 2017 Category: Cancer & Oncology Authors: Dierks J, Gaspersz MP, Belkouz A, van Vugt JLA, Coelen RJS, de Groot JWB, Ten Tije AJ, Meijer WG, Pruijt JFM, van Voorthuizen T, van Spronsen DJ, Rentinck M, Ten Oever D, Smit JM, Otten HM, van Gulik TM, Wilmink JW, Groot Koerkamp B, Klümpen H Tags: Acta Oncol Source Type: research